Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685815 · ClinicalTrials.gov registry record · Phase 2
Intravenous Iron Metabolism in Restless Legs Syndrome
A Phase 2 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00685815 is a Phase 2 study that has completed, run by American Regent. The registered enrollment target is 12 participants.
The verdict
NCT00685815, a Phase 2 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Double-blind, placebo-controlled, entitled: "Intravenous Iron Metabolism in Restless Legs Syndrome
Interventions
- DRUG Placebo
- DRUG Ferric Carboxymaltose (FCM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00685815
The ClinicalTrials.gov registry entry for NCT00685815 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00685815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00685815 about?
NCT00685815 is a clinical study titled "Intravenous Iron Metabolism in Restless Legs Syndrome". Double-blind, placebo-controlled, entitled: "Intravenous Iron Metabolism in Restless Legs Syndrome
What is the current status of trial NCT00685815?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2006-11. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00685815?
The interventions under investigation include: Placebo (DRUG), Ferric Carboxymaltose (FCM) (DRUG).
Who is sponsoring clinical trial NCT00685815?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.